Breaks Categories: News

MondayDec 19, 2016 2:54 pm

NetworkNewsBreaks – Amedica Corp. (NASDAQ: AMDA) Re-submits FDA Application following Positive Scientific Data

Amedica (NASDAQ: AMDA) this morning said it has re-filed an application with the FDA following encouraging results from a recent study showing rapid bone growth into porous silicon nitride. Explants of the company's porous silicon nitride from a large-animal model demonstrated bone healing into the material just four weeks after implantation. The new submission includes a modified CsC-based cervical implant that is comparable to Amedica’s own commercially-available Valeo®C cervical implants. "With this submission, the goal is to introduce our proprietary CsC technology platform into the U.S. market without further delay," Dr. B. Sonny Bal, Amedica CEO and president, stated in…

Continue Reading

MondayDec 19, 2016 12:23 pm

NetworkNewsBreaks – xG Technology, Inc. (NASDAQ: XGTI) Finalizes Deal to Acquire Vislink Communication Systems; Shares soar

Shares of xG Technology (NASDAQ: XGTI, XGTIW) are higher this morning after the company detailed its final definitive business purchase agreement to acquire Vislink Communication Systems from Vislink, Plc. The integration of Vislink is expected to add substantial revenue to xG's overall operations and offer the opportunity to realize numerous synergies with its IMT business unit. "The Vislink deal, which builds upon our prior purchase of IMT, underscores our plan to effect strategic acquisitions that further the Company's long-term growth objectives. In the same way that we were successful in achieving efficiencies in all our business operating areas after acquiring…

Continue Reading

WednesdayDec 14, 2016 2:04 pm

NetworkNewsBreaks – BrainStorm Cell Therapeutics (NASDAQ: BCLI) Trades Higher Following Positive Data from Phase 2 Study of NurOwn®

Shares of Brainstorm Cell Therapeutics, Inc. (NASDAQ: BCLI) are up 23% following the announcement that new, positive data from the company's phase 2 study of NurOwn® in ALS were presented by lead investigator Dr. James Berry at the 27th International Symposium on ALS/MND in Dublin, Ireland. The data showed disease symptoms were essentially halted for the period of the treatment effect. This effect was even more prominent in the pre-specified subgroup that was defined in order to exclude subjects whose disease was progressing slowly. "Importantly, there is evidence that NurOwn® may be halting disease progression or improving symptoms in some patients. The CSF biomarker profiles were…

Continue Reading

WednesdayDec 14, 2016 2:00 pm

NetworkNewsBreaks – Advanced Environmental Petroleum Producers (AEPP) Obtains Technical Evaluation Agreement; Moves forward with Pilot Plant

Advanced Environmental Petroleum Producers (OTCQB: AEPP) this morning said it had received clearance to manufacture and install the full Pilot Plant from its exclusive technology supplier Pointsource Processing (PSP) for the extraction of gas and oil after receiving the acceptance of its Technical Evaluation Agreement (TEA) for Block 19 Certificate. "AEPP can now instruct Chapman Petroleum Engineers from Calgary Alberta Canada to proceed on site to complete the 51-101 Petroleum Reserve Report for Block 19," Nigel Bosworth, AEPP's chief technology officer, stated in the news release. To view the full press release, visit: http://nnw.fm/gTy1C About Advanced Environmental Petroleum Producers, Inc.…

Continue Reading

TuesdayDec 13, 2016 3:01 pm

NetworkNewsBreaks – Revance Therapeutics, Inc. (RVNC) Reports Positive Preliminary from Phase 2 Cervical Dystonia Trial

Shares of Revance Therapeutics (NASDAQ: RVNC) are ticking higher after the biotech company reported positive interim results from its U.S. phase 2 open-label, dose-escalating clinical study of DaxibotulinumtoxinA Injectable (RT002) to treat moderate-to-severe isolated cervical dystonia in adults, a movement disorder of the neck. Final results are expected in the first half of 2017. “ … I am particularly encouraged that in this trial RT002 exhibited a safety profile at least as good as currently marketed neurotoxins. Furthermore, with a sustained median duration of at least 24 weeks, there is a possibility that patients will require injections only two times…

Continue Reading

TuesdayDec 13, 2016 2:51 pm

NetworkNewsBreaks – Organovo (ONVO) Presenting 3D Bioprinted Human Liver Tissue Data at TERMIS-Americas Meeting

Organovo Holdings, Inc. (NASDAQ: ONVO) is presenting the first data showing survival and sustained functionality of its 3D bioprinted human liver tissue when implanted into animal models at the ongoing TERMIS-Americas Meeting in San Diego. Organovo intends to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its therapeutic liver tissue in three to five years. “Our preclinical data show rapid vascularization and tissue engraftment, and evidence of function and durability of our 3D bioprinted human liver tissue over several weeks.  Most importantly, we see evidence of stable production of key human liver…

Continue Reading

TuesdayDec 13, 2016 2:45 pm

NetworkNewsBreaks – Soligenix, Inc. (SNGX) Prices $5,277,000 Public Offering, Debuts on Nasdaq

Soligenix (NASDAQ: SNGX, SNGXW) shares are 34% lower on its first day of uplisting to the Nasdaq Capital Market. The late-stage biopharmaceutical company this morning priced an underwritten public offering of 1,670,000 shares of its common stock and warrants to purchase up to an aggregate of 2,087,500 shares of its common stock at a combined offering price of $3.16 – for gross proceeds of approximately $5,277,200. The warrants will have an initial per share exercise price of $3.95, subject to customary adjustment in connection with stock splits, stock dividends, reclassifications, combinations and other similar events; are exercisable immediately; and will…

Continue Reading

TuesdayDec 13, 2016 2:08 pm

NetworkNewsBreaks – Neovasc, Inc. (NVCN), Boston Scientific Corp. (BSX) Close $75M Acquisition Deal; Shares of Both Higher

Neovasc (NASDAQ: NVCN) and Boston Scientific (NYSE: BSX) this morning reported the close of their previously announced $75 million agreement in which Boston Scientific has acquired Neovasc's advanced biologic tissue capabilities and certain manufacturing assets, as well as 11,817,000 common shares at a price of $0.60 each ($7.0 million) for a 15% equity interest in Neovasc. Per the agreement, Neovasc has been granted a license to the purchased assets and access to the facilities in order to continue its assembly activities for its remaining tissue and valve customers. Neovasc said it intends to use the proceeds of these transactions toward…

Continue Reading

MondayDec 12, 2016 1:39 pm

NetworkNewsBreaks – Nano Dimension (NNDM): Capabilities of “Holy Grail of 3D Printers” on Display at CES 2017

Nano Dimension (NASDAQ, TASE: NNDM) this morning said it will showcase its DragonFly 2020™  3D printer during CES 2017, an annual global consumer electronics and consumer technology tradeshow taking place January 5-8, 2017,  in Las Vegas, Nevada. Visitors to Nano Dimension’s booth will see a wide range of fully functioning circuits printed by the 'Holy Grail of 3D Printers' – a label given to DragonFly 2020 by CNET at last year’s CES tradeshow. "Nano Dimension prints 3D-print circuitry in non-planar free-form circuits, which is an enormous area of untapped potential. There's no doubt that 3D printing will shape the design…

Continue Reading

MondayDec 12, 2016 1:36 pm

NetworkNewsBreaks – Jaguar Animal Health (JAGX) Inks Distribution Deal with Henry Shein, Inc.; Shares Spike

Shares of Jaguar Animal Health, Inc. (NASDAQ: JAGX) are up 23%, triggered by news of the company’s agreement with Henry Schein, Inc. for one year of exclusive distribution of Jaguar’s Neonorm™ Foal product to the U.S. equine market. “We are very excited to have the support of one the world’s leading companion animal health distribution companies in our effort to drive sales of Neonorm™ Foal throughout the U.S. equine market,” Lisa Conte, Jaguar’s president and CEO, stated in the news release. “We look forward to leveraging the great exposure that Neonorm™ Foal received at last week’s AAEP conference and collaborating closely…

Continue Reading